Cyanamide 3,4-dihydro-2H-1,4-thiazine compounds, pharmaceutical compositions thereof and methods of preparation and use thereof

3,4-dihydro-2H-1,4-thiazine compounds were synthesized via a long-range cyano migration reaction promoted by inorganic thiocyanate, solving the water solubility and stability problems of existing ferroptosis inducers and achieving safe and efficient synthesis of cyanamide compounds with antitumor activity.

CN123106578APending Publication Date: 2026-11-17NANKAI UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611155908.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-31
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing ferroptosis inducers suffer from poor water solubility, insufficient stability, and unsatisfactory selectivity. Furthermore, the synthesis of cyanamide compounds relies on highly toxic cyaniding reagents, which limits their application in drug discovery.

Method used

Using inorganic thiocyanate as the cyanide source, N–CN bonds are constructed through selective thiocyanation and intramolecular tandem cyclization reactions to synthesize 3,4-dihydro-2H-1,4-thiazine compounds. This avoids the use of highly toxic cyaniding reagents, and the reaction conditions are mild and have a wide range of applications.

Benefits of technology

This study achieved efficient and safe construction of cyanamide compounds, improving the safety and environmental friendliness of the synthesis process and simplifying the synthesis procedure. The compounds exhibited excellent inhibitory activity against non-small cell lung cancer cells and have promising prospects for drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106578A_ABST
    Figure CN123106578A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology, specifically relating to cyanamide-based 3,4-dihydro-2H-1,4-thiazide compounds, their pharmaceutical compositions, preparation methods, and uses, particularly a cyanamide-based 3,4-dihydro-2H-1,4-thiazide compound or its salt as shown in formula (II), for the treatment of cancer, pharmaceutical compositions containing a therapeutically effective amount of a cyanamide-based 3,4-dihydro-2H-1,4-thiazide compound (II) and a pharmaceutically acceptable carrier, or compositions with other anticancer drugs, methods for preparing the cyanamide-based 3,4-dihydro-2H-1,4-thiazide compound or its salt, and its use in pharmaceuticals, particularly in the preparation of drugs for treating cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the fields of organic synthesis and medicinal chemistry, specifically relating to a 3,4-dihydro-2H-1,4-thiazine compound with potent and selective ferroptosis-inducing activity, its synthesis method, biological activity, and application in the preparation of antitumor drugs. More specifically, this invention relates to a method for constructing a 3,4-dihydro-2H-1,4-thiazine skeleton containing a cyanamine functional group using N-propynyl β-enamine ketone as a substrate and inorganic thiocyanate as a cyanide source through selective thiocyanation, intramolecular tandem cyclization, and long-range S→N cyano migration reaction, and the application of this type of compound in the preparation of antitumor drugs, especially anti-lung cancer drugs. Background Technology

[0002] Cancer cells often acquire multidrug resistance through mechanisms such as gene mutation, overexpression of anti-apoptotic proteins, and upregulation of drug efflux pumps, leading to tumor recurrence and metastasis. Taking non-small cell lung cancer as an example, approximately 50% to 60% of patients develop acquired resistance within one year of receiving treatment with first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, resulting in treatment failure, often accompanied by increased tumor dedifferentiation and metastatic ability.

[0003] Ferroptosis, a programmed cell death mechanism dependent on iron accumulation and lipid peroxidation, has recently been recognized as a crucial strategy for overcoming apoptosis resistance in tumor cells. Particularly in malignant tumors such as non-small cell lung cancer, resistance to traditional chemotherapy and targeted therapy often arises due to mechanisms such as gene mutations, overexpression of anti-apoptotic proteins, and drug efflux, leading to relapse and metastasis. Therefore, developing novel anti-tumor small molecules that exert their effects by inducing ferroptosis is of great significance.

[0004] However, despite the rapid progress in ferroptosis research, its clinical translation remains significantly limited. Existing widely used ferroptosis inducers, such as erastin and RSL3, generally suffer from poor water solubility, insufficient stability, and unsatisfactory selectivity, restricting their further development and application. To date, no ferroptosis inducer has been approved for marketing. Therefore, developing novel ferroptosis inducers with higher activity, better selectivity, and superior pharmaceutical properties is of significant research importance and application value.

[0005] Cyanamine structural units are widely found in drug molecules and bioactive compounds. Introducing cyanamine groups can significantly improve the membrane permeability and metabolic stability of molecules. However, the synthesis of cyanamine compounds has long been limited by the inherent difficulty in constructing N–CN bonds. Existing methods mostly rely on highly toxic and unstable cyaniding reagents such as cyanogen bromide, trimethylsilyl cyanide, or pre-prepared electrophilic cyaniding reagents (such as N-cyanobenzenesulfonamide, cyanobenzoxazolone, etc.). These reagents are not only highly toxic and expensive, but also require harsh reaction conditions and have poor atom economy, limiting the widespread application of cyanamine compounds in drug discovery.

[0006] In recent years, inorganic thiocyanates (such as potassium thiocyanate and ammonium thiocyanate) have been used as "green cyanide sources" to achieve the construction of various C–CN bonds due to their low cost, low toxicity, and ease of operation. However, methods for directly constructing N–CN bonds using thiocyanates, especially for synthesizing cyanamide compounds through long-range cyano migration strategies, have not yet been reported.

[0007] On the other hand, N-propargyl-β-enamine ketones are an important class of synthetic building blocks. Under alkaline conditions, they can undergo propargyl-allene isomerization to form highly reactive intermediates, which can then undergo various tandem cyclization reactions to construct nitrogen-containing or heteroatom-containing heterocyclic skeletons. However, current technology lacks a method for directly constructing 3,4-dihydro-2H-1,4-thiazine compounds containing cyanamine functional groups via programmed tandem reactions of N-propargyl-β-enamine ketones and inorganic thiocyanates. Therefore, developing a synthetic method that uses inexpensive, low-toxicity inorganic thiocyanates as the cyanide source, requires no metal catalysis, operates under mild reaction conditions, and efficiently constructs N-CN bonds to obtain novel 3,4-dihydro-2H-1,4-thiazine compounds with excellent antitumor activity is of significant scientific and practical value. Summary of the Invention

[0008] Purpose of the invention The purpose of this invention is to overcome the problems in the prior art, such as reliance on highly toxic cyaniding reagents, difficulty in constructing N-CN bonds, and harsh conditions in cyanamide synthesis. This invention provides a method for synthesizing cyanamide-type 3,4-dihydro-2H-1,4-thiazine compounds via long-range cyano migration promoted by inorganic thiocyanate.

[0009] Another object of the present invention is to provide the biological activity of the above-mentioned compounds, especially their antitumor activity.

[0010] Another object of the present invention is to provide the use of the above-mentioned compounds in the preparation of antitumor drugs.

[0011] Technical solution This invention provides a cyanamide-based 3,4-dihydro-2H-1,4-thiazine compound of formula (II). .

[0012] Wherein, R1 and R2 are aryl or heterocyclic groups, wherein the aryl group is phenyl or substituted phenyl, and the heteroaryl group is furanyl, thiophene, substituted furanyl, or substituted thiophene.

[0013] Preferably, compounds IIa-IIs A method for preparing compound (II) includes the following steps: (1) using N-propargyl enamine ketone (I) as raw material, 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (DBDMH) as bromination promoter, inorganic thiocyanate as cyanide source, and a certain reaction solvent, mixing them in a certain proportion, and at a certain temperature, N-propargyl enamine ketone first undergoes selective thiocyanation reaction to generate thiocyanate intermediate; (2) without separation, sodium hydroxide and crown ether are directly added to the intermediate, and at a certain temperature, the reaction is carried out to obtain 3,4-dihydro-2H-1,4-thiazine compound (II).

[0014] According to the preparation method described above, the N-propyne β-enamine ketone has the structure shown in formula (I). .

[0015] According to the method described above, the molar ratio of N-propargylenamine ketone (I), 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione, potassium thiocyanate, sodium hydroxide and 15-ether-5 is 1.0:0.5:1.0:1.0:1.0.

[0016] According to the method described above, the inorganic thiocyanate in step (1) is selected from one or more of potassium thiocyanate, sodium thiocyanate, or ammonium thiocyanate.

[0017] According to the method described above, the organic solvent in step (1) is N,N-dimethylformamide.

[0018] According to the method described above, the reaction temperature in step (1) is 40 to 80°C, preferably 60°C.

[0019] According to the method described above, the crown ether in step (2) is 15-crown ether-5.

[0020] According to the method described above, the reaction temperature in step (2) is 0 to 80°C, preferably 25°C.

[0021] According to the use of the compound as described above in the preparation of a medicament for treating cancer or an adjuvant medicament for treating cancer, wherein the cancer is leukemia, breast cancer, prostate cancer, nasopharyngeal carcinoma, colorectal cancer, lung cancer, liver cancer, esophageal cancer, gastric cancer, intestinal cancer, kidney cancer, oral cancer, Hodgkin's lymphoma, pancreatic cancer, rectal cancer, cervical cancer, non-Hodgkin's lymphoma, glioma, melanoma, bladder cancer, ovarian cancer, thyroid cancer, or Kaposi's sarcoma.

[0022] A pharmaceutical composition for treating cancer, said pharmaceutical composition comprising an effective amount of the compound as described above and a pharmaceutically acceptable carrier or other anticancer drug.

[0023] Beneficial effects Compared with the prior art, the present invention has the following advantages: This invention pioneers the use of inorganic thiocyanate as a green cyanide source to achieve long-range S→N cyanide migration. Existing synthesis of cyanamide compounds often relies on highly toxic and unstable cyaniding reagents (such as BrCN and TMSCN) or pre-prepared electrophilic cyaniding reagents. This invention, for the first time, uses inexpensive, low-toxicity, and readily available inorganic thiocyanate (KSCN) as the cyanide source. Through a designed cascade reaction involving long-range sulfur→nitrocyanide migration, an N–CN bond is successfully constructed, fundamentally avoiding the use of highly toxic cyanides and significantly improving the safety, environmental friendliness, and practicality of the synthesis process.

[0024] The reaction conditions are mild and require no transition metal catalysis. This invention can be carried out under metal-free, mild alkaline conditions (reaction temperature from room temperature to 60°C), without the need for precious metal catalysts or highly corrosive conditions, thus reducing production costs and environmental pollution, and exhibiting excellent tolerance to a variety of functional groups.

[0025] A simple one-pot tandem process. This invention integrates multiple steps, including thiocyanate introduction, propargyl-allene isomerization, intramolecular thiazine cyclization, S-CN selective cleavage, and long-range cyano migration, into a one-pot operation. This eliminates the need to separate intermediates, simplifying the synthesis process and improving synthesis efficiency and atom economy.

[0026] The method of this invention has a wide range of applicable substrates and high structural diversity. It is well tolerant to substituents with different electronegativity (electron-donating, electron-withdrawing) and steric hindrance (ortho, meta, para) on aromatic rings, naphthalene rings, heterocycles (furan, thiophene), and ester groups, and is compatible with disubstituted aromatic substrates. It can efficiently construct a library of 3,4-dihydro-2H-1,4-thiazine-cyanamide compounds with diverse structures.

[0027] The compounds obtained in this invention exhibit excellent inhibitory activity against non-small cell lung cancer cells NCI-H820, with some compounds reaching nanomolar levels.

[0028] In a lung cancer patient-derived xenograft tumor model, representative compounds II-b and II-c can significantly inhibit tumor volume and tumor weight, showing promising potential for drug development. Attached Figure Description

[0029] Appendix Figure 1 Compounds II-c and II-b inhibited PDX tumor growth. (A) Tumor images of mice in different PDX xenograft groups at sacrifice. (B) Tumor growth curves of different PDX xenograft groups. (C) Tumor weight of mice in different PDX xenograft groups at sacrifice. **p < 0.01, ***p < 0.005 (n=5). Detailed Implementation

[0030] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of this invention will be clearly and completely described below. Obviously, the described embodiments are only a part of the embodiments of this invention, and not all of them. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention. To further illustrate the technical means and effects adopted by this invention, the invention will be described in detail below with reference to specific embodiments.

[0031] The N-substituted enaminones used in this invention are the required reaction raw materials, prepared according to the literature method. (Cacchi, S.; Fabrizi, G.; Filisti, E. N-Propargylic β-Enaminones: Common Intermediates for the Synthesis of Polysubstituted Pyrroles and Pyridines. Org. Lett. 2008, 10 (13), 2629–2632.)

[0032] The 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione, potassium thiocyanate, N,N-dimethylformamide, sodium hydroxide, 15-crown ether-5, ethyl acetate, sodium chloride, anhydrous sodium sulfate, etc. used in this invention are all commercially available.

[0033] The present invention will be further described below with reference to specific embodiments, but this does not limit the present invention.

[0034] Example 1: Preparation of compounds II-a to II-an 1. Preparation of compound II-a: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1,3-diphenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-a. Yield: 451 mg, 71%. Melting point: 163–165 °C. 1 H NMR (400 MHz, CDCl3): d = 7.59–7.53 (m, 2H), 7.31–7.27 (m, 1H), 7.25–7.20 (m, 2H), 7.18–7.11 (m, 5H), 5.55 (d, J = 1.1 Hz, 1H), 5.38 (d, J =1.4 Hz, 1H), 4.38 (s, 2H). 13 C NMR (100 MHz, CDCl3): d = 192.8, 140.6, 136.6,132.8, 132.7, 132.0, 130.8, 130.0, 129.3, 128.6, 128.0, 117.3, 113.0, 112.6,54.9. HRMS (ESI): m / z [M+H] + calcd for: C 19 H 15 N2OS: 319.0905; found: 319.0908. 2. Preparation of compound II-b: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(4-methoxyphenyl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-b. Yield: 445 mg, 64%. Melting point: 149–151 °C. 1 H NMR (400 MHz, CDCl3): d = 7.66–7.61 (m, 2H), 7.29–7.26(m, 2H), 7.21–7.16 (m, 3H), 6.71–6.67 (m, 2H), 5.53 (d, J = 1.2 Hz, 1H), 5.37(d, J = 1.1 Hz, 1H), 4.36 (s, 2H), 3.76 (s, 3H). 13 C NMR (100 MHz, CDCl3): d HRMS (ESI): m / z [M + H] + calcd for:C 20 H17 N2O2S: 349.1011; found: 349.1013. 3. Preparation of compound II-c: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-phenyl-3-(prop-2-yn-1-ylamino)-1-(p-tolyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-c. Yield: 498 mg, 75%. Melting point: 160–162 °C. 1 H NMR (400 MHz, CDCl3): d = 7.51 (d, J = 8.2 Hz, 2H),7.26–7.23 (m, 2H), 7.20–7.13 (m, 3H), 6.99 (d, J = 7.9 Hz, 2H), 5.54 (d, J =1.2 Hz, 1H), 5.37 (d, J = 1.2 Hz, 1H), 4.37 (s, 2H), 2.26 (s, 3H). 13 C NMR (100 MHz, CDCl3): dHRMS (ESI): m / z [M + H] + calcd for: C 20 H 17 N2OS: 333.1062; found: 333.1065. 4. Preparation of compound II-d: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(4-fluorophenyl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-d. Yield: 403 mg, 60%. Melting point: 112–114 °C. 1 H NMR (400 MHz, CDCl3): d = 7.62–7.55 (m, 2H), 7.25–7.14(m, 5H), 6.83 (t, J = 8.6 Hz, 2H), 5.56 (s, 1H), 5.39 (s, 1H), 4.38 (s, 2H). 13 C NMR (100 MHz, CDCl3): d= 191.3, 165.2 (d, J C-F = 254 Hz), 140.6, 132.9 (d, J C-F = 3 Hz), 132.6, 131.9, 131.8 (d, J C-F = 9 Hz), 131.0, 129.9, 128.8, 117.1,115.2 (d, J C-F = 22 Hz), 113.1, 112.5, 54.9. 19 F NMR (376 MHz, CDCl3): d = -104.67 (s, F). HRMS (ESI): m / z [M + H] + calcd for: C 19 H 14 N2OSF: 337.0811; found: 337.0816. 5. Preparation of compound II-e: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(4-chlorophenyl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-e. Yield: 429 mg, 61%. Melting point: 178 °C.1 H NMR (400 MHz, CDCl3): d =7.51–7.47 (m, 2H), 7.25–7.21 (m,3H), 7.20–7.16 (m, 2H), 7.15–7.11 (m, 2H), 5.57 (d, J = 1.1 Hz, 1H), 5.40 (d, J = 1.2 Hz, 1H), 4.39 (s, 2H). 13 C NMR (100 MHz, CDCl3): d = 191.6, 141.0,139.0, 135.0, 132.5, 131.9, 131.2, 130.6, 130.0, 128.8, 128.3, 116.9, 113.2,112.5, 54.9. HRMS (ESI): m / z [M + H] + calcd for:C 19 H 14 N2OSCl : 353.0515; found:353.0518. 6. Preparation of compound II-f: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(4-bromophenyl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-f. Yield: 498 mg, 63%. Melting point: 174–175 °C. 1 H NMR (400 MHz, CDCl3): d = 7.42–7.38 (m, 2H), 7.31–7.26(m, 2H), 7.24–7.14 (m, 5H), 5.56 (d, J = 1.2 Hz, 1H), 5.39 (d, J = 1.1 Hz, 1H), 4.38 (s, 2H). 13 C NMR (100 MHz, CDCl3): d = 191.7, 141.1, 135.4, 132.5,131.8, 131.3, 131.1, 130.6, 130.0, 128.8, 127.7, 116.9, 113.2, 112.4, 54.8.HRMS (ESI): m / z [M + H] + calcd for: C 19 H 14 BrN2OS: 397.0010; found: 397.0008. 7. Preparation of compound II-g: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-phenyl-3-(prop-2-yn-1-ylamino)-1-(4-(trifluoromethoxy)phenyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-g. Yield: 498 mg, 62%. Melting point: 136–139 °C. 1 H NMR (400 MHz, CDCl3): d = 7.57–7.53 (m, 2H), 7.23–7.12 (m, 5H), 6.97–6.93 (m, 2H), 5.58 (d, J = 1.3 Hz, 1H), 5.41 (d, J = 1.2Hz, 1H), 4.40 (d, J = 0.9 Hz, 2H). 13 C NMR (100 MHz, CDCl3): d = 191.4, 151.8,141.8, 135.1, 132.5, 132.2, 131.9, 131.2, 131.1, 130.2, 128.8, 119.9, 117.1,113.3, 112.4, 54.9. 19 F NMR (376 MHz, CDCl3): d = -57.72 (s, 3F). HRMS (ESI):m / z [M + H]+ calcd for: C 20 H 14 N2O2SF3: 403.0728; found: 403.0728. 8. Preparation of compound II-h: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(4-(tert-butyl)phenyl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-h. Yield: 374 mg, 50%. Melting point: 175–176 °C. 1 H NMR (400 MHz, CDCl3): d = 7.55–7.49 (m, 2H), 7.25–7.20(m, 2H), 7.20–7.11 (m, 5H), 5.53 (d, J = 1.0 Hz, 1H), 5.37 (d, J = 4.0 Hz,1H), 4.37 (s, 2H), 1.21 (s, 9H). 13 C NMR (100 MHz, CDCl3): d= 192.3, 156.5,140.0, 133.7, 132.9, 132.1, 130.6, 129.9, 129.4, 128.5, 124.9, 117.6, 112.7,54.8, 34.9, 30.8. HRMS (ESI): m / z [M + H] + calcd for: C 23 H 23 N2OS: 375.1531; found: 375.1535. 9. Preparation of compound II-i: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-phenyl-3-(prop-2-yn-1-ylamino)-1-(4-(prop-2-en-1-yloxy)phenyl)prop-2-en-1one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-i. Yield: 312 mg, 42%. Melting point: 104–107 °C. 1 H NMR (400 MHz, CDCl3): d = 7.66–7.60 (m,2H), 7.29–7.24 (m, 2H), 7.22–7.14 (m, 3H), 6.76 (d, J = 8.9 Hz, 2H), 5.54 (d, J = 1.2 Hz, 1H), 5.37 (d, J= 1.2 Hz, 1H), 4.64 (d, J = 2.4 Hz, 2H), 4.37 (s,2H), 2.52 (t, J = 2.4 Hz, 1H). 13 C NMR (100 MHz, CDCl3): d = 191.0, 161.2,139.0, 132.7, 132.1, 131.7, 130.7, 129.8, 129.7, 128.6, 117.4, 114.2, 112.8,112.7, 77.5, 76.1, 55.8, 54.7. HRMS (ESI): m / z [M + H] + calcd for: C 22 H 17 N2O2S:373.1011; found: 373.1015. 10. Preparation of compound II-i: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(3-methoxyphenyl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-j. Yield: 417 mg, 60%. Melting point: 143–146 °C. 1 H NMR (400 MHz, CDCl3): d= 7.26–7.23 (m, 2H), 7.22–7.13(m, 4H), 7.10–7.04 (m, 2H), 6.87–6.82 (m, 1H), 5.55 (d, J = 1.0 Hz, 1H), 5.38(d, J = 0.8 Hz, 1H), 4.38 (s, 2H), 3.74 (s, 3H). 13 C NMR (100 MHz, CDCl3): d =192.5, 159.1, 140.5, 137.8, 132.8, 132.1, 130.8, 130.0, 129.0, 128.6, 122.2,119.2, 117.4, 113.7, 112.9, 112.6, 55.4, 54.9. HRMS (ESI): m / z [M + H] + calcdfor: C 20 H 17 N2O2S: 349.1011; found: 349.1011. 11. Preparation of compound II-k: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-phenyl-3-(prop-2-yn-1-ylamino)-1-(m-tolyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-k. Yield: 438 mg, 66%. Melting point: 144–146 °C. 1 H NMR (400 MHz, CDCl3): d = 7.40–7.33 (m, 2H), 7.25–7.22(m, 2H), 7.17– 7.03 (m, 5H), 5.54 (d, J = 0.8 Hz, 1H), 5.37 (d, J = 0.7 Hz,1H), 4.38 (s, 2H), 2.23 (s, 3H). 13 C NMR (100 MHz, CDCl3): d = 192.8, 140.5,137.7, 136.4, 133.5, 132.9, 132.1, 130.8, 129.9, 129.8, 128.6, 127.9, 126.6,117.5, 112.8, 112.7, 54.9, 21.1. HRMS (ESI): m / z [M + H] + calcd for:C 20 H 17 N2OS: 333.1062; found: 333.1065. 12. Preparation of compound II-l: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(3-fluorophenyl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-l. Yield: 322 mg, 48%. Melting point: 154–157 °C. 1 H NMR (400 MHz, CDCl3): d = 7.33–7.28 (m, 1H), 7.25–7.08(m, 7H), 6.99-6.93 (m, 1H), 5.57 (s, 1H), 5.40 (s, 1H), 4.40 (s, 2H). 13 C NMR (100 MHz, CDCl3): d = 191.6, 161.9 (d, J C-F = 246 Hz), 141.7, 138.8 (d, J C-F = 6Hz),132.6, 131.9, 131.2, 130.1, 129.6 (d, J C-F = 8 Hz), 128.7, 124.9 (d, J C-F =3 Hz), 119.5 (d,J C-F = 21Hz), 116.9, 115.8 (d, J C-F = 22Hz), 113.2, 112.4, 54.9. 19 F NMR (376 MHz, CDCl3): d = -112.48 (s, F). HRMS (ESI): m / z [M + H] + calcdfor: C 19 H 14 FN2OS: 337.0811; found: 337.0813. 13. Preparation of compound II-m: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(3-chlorophenyl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-m. Yield: 366 mg, 52%. Melting point: 182–184 °C. 1 H NMR (400 MHz, CDCl3): d = 7.43–7.38 (m, 2H), 7.25–7.16(m, 6H), 7.08 (t, J = 7.8 Hz, 1H), 5.58 (d, J= 1.0 Hz, 1H), 5.40 (d, J = 0.9Hz, 1H), 4.41 (s, 2H). 13 C NMR (100 MHz, CDCl3): d = 191.5, 142.2, 138.3,133.9, 132.6, 132.3, 131.9, 131.3, 130.2, 129.3, 129.2, 128.8, 127.1, 116.9,113.2, 112.3, 54.9. HRMS (ESI): m / z [M + H] + calcd for: C 19 H 14 N2OSCl: 353.0515; found: 353.0509. 14. Preparation of compound II-n: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(naphthyl-2-yl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-n. Yield: 456 mg, 62%. Melting point: 150–151 °C. 1 H NMR (400 MHz, CDCl3): d= 7.68–7.64 (m, 2H), 7.51–7.47(m, 2H), 7.46–7.37 (m, 5H), 7.29–7.27 (m, 1H), 7.17–7.15 (m, 2H), 5.57 (d, J = 1.2 Hz, 1H), 5.40 (d, J = 1.1 Hz, 1H), 4.41 (s, 2H). 13 C NMR (100 MHz, CDCl3): d = 192.3, 145.4, 140.4, 139.6, 135.2, 132.8, 132.1, 130.8, 130.0,129.9, 128.9, 128.7, 128.2, 127.1, 126.6, 117.4, 112.9, 112.7, 54.9. HRMS(ESI): m / z [M + H] + calcd for: C 23 H 17 N2OS: 369.1062; found: 369.1066. 15. Preparation of compound II-o: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(naphthyl-1-yl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-o. Yield: 345 mg, 47%. Melting point: 150–152 °C. 1 H NMR (400 MHz, CDCl3): d = 8.23 ​​(dd, J = 8.6, 1.1 Hz,1H), 7.68–7.60 (m, 2H), 7.56–7.41 (m, 3H), 7.16–7.01 (m, 3H), 6.87–6.75 (m,3H), 5.61 (d, J = 1.0 Hz, 1H), 5.40 (d, J = 1.1 Hz, 1H), 4.42 (s, 2H). 13 C NMR (100 MHz, CDCl3): d = 193.8, 144.2, 135.8, 133.2, 133.0, 132.1, 132.0, 130.5,130.3, 129.8, 128.3, 128.0, 127.5, 126.2, 125.1, 123.7, 119.7, 113.1, 112.2,55.0. HRMS (ESI): m / z [M + H] + calcd for: C23 H 17 N2OS: 369.1062; found:369.1059. 16. Preparation of compound II-p: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(furan-2-yl)-3-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-p. Yield: 396 mg, 60%. Melting point: 128–130 °C. 1 H NMR (400 MHz, CDCl3): d = 7.37–7.33 (m, 2H), 7.29–7.26(m, 3H), 7.26–7.22 (m, 1H), 6.89 (dd, J = 3.6, 0.6 Hz, 1H), 6.24 (dd, J =3.6, 1.7 Hz, 1H), 5.54 (d, J = 1.0 Hz, 1H), 5.37 (d, J = 0.8 Hz, 1H), 4.35 (s, 2H). 13 C NMR (100 MHz, CDCl3): d= 179.4, 151.1, 146.7, 140.9, 132.9,132.3, 130.8, 129.6, 128.7, 119.7, 116.6, 112.9, 112.6, 112.3, 54.9. HRMS(ESI): m / z [M+Na] + calcd for:C 17 H 12 N2O2NaS: 331.0517; found: 331.0522. 17. Preparation of compound II-q: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-phenyl-3-(prop-2-yn-1-ylamino)-1-(thiophen-2-yl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-q. Yield: 401 mg, 62%. Melting point: 163–166 °C. 1 H NMR (400 MHz, CDCl3): d = 7.48–7.45 (m, 1H), 7.40–7.37(m, 1H), 7.37–7.33 (m, 2H), 7.25–7.22 (m, 2H), 6.84 (dd, J = 4.9, 3.9 Hz, 1H), 5.55 (d, J = 1.1 Hz, 1H), 5.39 (d,J = 0.9 Hz, 1H), 4.36 (s, 2H). 13 C NMR (100 MHz, CDCl3): d = 184.2, 142.4, 138.8, 134.9, 134.6, 132.6, 132.2, 130.8,129.7, 128.8, 127.7, 117.6, 113.1, 112.7, 54.8. HRMS (ESI): m / z [M + H] + calcd for:C 17 H 13 N2OS2: 325.0469; found: 325.0470. 18. Preparation of compound II-r: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-phenyl-3-(prop-2-yn-1-ylamino)acrylate (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-r. Yield: 343 mg, 60%. Melting point: 112–113 °C. 1 H NMR (400 MHz, CDCl3): d = 7.47–7.40 (m, 3H), 7.37–7.33 (m, 2H), 5.53 (s,1H), 5.33 (s, 1H), 4.28 (s, 2H), 3.97 (q,J = 7.1 Hz, 2H), 0.92 (t, J = 7.1Hz, 3H). 13 C NMR (100 MHz, CDCl3): d = 163.9, 142.6, 133.2, 132.1, 130.5,129.2, 128.6, 113.1, 112.2, 108.6, 61.6, 54.6, 13.4. HRMS (ESI): m / z [M + H] + calcd for: C 15 H 15 N2O2S: 287.0854; found: 287.0856. 19. Preparation of compound II-s: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(4-methoxyphenyl)-1-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-s. Yield: 417 mg, 60%. Melting point: 67–70 °C. 1 H NMR (400 MHz, CDCl3): d= 7.60–7.49 (m, 2H), 7.31–7.26(m, 1H), 7.19–7.13 (m, 4H), 6.67–6.61 (m, 2H), 5.53 (d, J = 0.8 Hz, 1H), 5.36(d, J = 0.7 Hz, 1H), 4.37 (s, 2H), 3.67 (s, 3H). 13 C NMR (100 MHz, CDCl3): d =193.0, 161.5, 141.5, 136.8, 133.4, 132.5, 131.7, 129.2, 127.9, 124.4, 115.9,114.1, 112.8, 112.5, 55.3, 55.1. HRMS (ESI): m / z [M + H] + calcd for:C 20 H 17 N2O2S: 349.1011; found: 349.1015. 20. Preparation of compound II-t: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-phenyl-3-(prop-2-yn-1-ylamino)-3-(4-methylphenyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-t. Yield: 365 mg, 55%. Melting point: 129–132 °C. 1 H NMR (400 MHz, CDCl3): d = 7.59–7.53 (m, 2H), 7.33–7.27(m, 1H), 7.20–7.08 (m, 4H), 6.93 (d, J = 7.9 Hz, 2H), 5.53 (d, J = 0.8 Hz, 1H), 5.36 (d, J = 0.6 Hz, 1H), 4.37 (s, 2H), 2.17 (s, 3H). 13 C NMR (101 MHz, CDCl3): d HRMS (ESI): m / z [M + H] + calcdfor: C 20 H 17N2OS: 333.1062; found: 333.1063. 21. Preparation of compound II-u: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(4-fluorophenyl)-1-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-u. Yield: 383 mg, 57%. Melting point: 165–168 °C. 1 H NMR (400 MHz, CDCl3): d = 7.58–7.53 (m, 2H), 7.37–7.31(m, 1H), 7.25–7.17 (m, 4H), 6.88–6.80 (m, 2H), 5.57 (d, J = 1.1 Hz, 1H), 5.40(d, J = 0.9 Hz, 1H), 4.38 (s, 2H). 13 C NMR (101 MHz, CDCl3): d = 192.6, 163.9(d, J C-F = 252 Hz), 139.3, 136.5, 133.0, 132.6, 132.1(d, J C-F = 9 Hz), 129.3, 128.2 (d,J C-F = 3 Hz), 128.1, 117.6, 115.9 (d, J C-F = 22 Hz), 113.2, 112.5, 54.9. 19 F NMR (376 MHz, CDCl3): d = -107.92 (s, F). HRMS (ESI): m / z [M + H] + calcd for: C 19 H 14 N2OSF: 337.0811; found: 337.0812. 22. Preparation of compound II-v: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(4-chlorophenyl)-1-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-v. Yield: 387 mg, 55%. Melting point: 173–176 °C. 1 H NMR (400 MHz, CDCl3): d = 7.61–7.55 (m, 2H), 7.37 (t, J = 7.4 Hz, 1H), 7.24–7.10 (m, 6H), 5.57 (d, J= 0.8 Hz, 1H), 5.40 (s, 1H), 4.37 (s, 2H). 13 C NMR (101 MHz, CDCl3): d = 192.5, 138.8, 137.0, 136.3, 133.1,132.4, 131.1, 130.5, 129.3, 129.0, 128.2, 118.2, 113.4, 112.5, 54.7. HRMS(ESI): m / z [M + H] + calcd for: C 19 H 14 N2OSCl: 353.0515; found: 353.0519. 23. Preparation of compound II-w: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(4-tert-butylphenyl)-1-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-w. Yield: 403 mg, 54%. Melting point: 173–177 °C. 1 H NMR (400 MHz, CDCl3): d = 7.49–7.44 (m, 2H), 7.21 (t, J= 7.4 Hz, 1H), 7.15–7.06 (m, 6H), 5.54 (s, 1H), 5.37 (s, 1H), 4.39 (s, 2H), 1.13 (s, 9H). 13 C NMR (101 MHz, CDCl3): d = 193.1, 154.3, 141.9, 137.0, 133.2,132.1, 130.0, 129.1, 129.0, 127.7, 125.5, 116.8, 112.7, 112.6, 55.0, 34.7,30.8. HRMS (ESI): m / z [M + H] + calcd for: C 23 H 23 N2OS: 375.1531; found:375.1534. 24. Preparation of compound II-x: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(3-methoxyphenyl)-1-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-x. Yield: 382 mg, 55%. Melting point: 79–81 °C. 1 H NMR (400 MHz, CDCl3): d= 7.60–7.55 (m, 2H), 7.34–7.29(m, 1H), 7.21–7.15 (m, 2H), 7.05 (t, J = 7.9 Hz, 1H), 6.88–6.83 (m, 1H), 6.74–6.67 (m, 2H), 5.55 (d, J = 1.2 Hz, 1H), 5.38 (d, J = 1.2 Hz, 1H), 4.37(s, 2H), 3.65 (s, 3H).13C NMR (101 MHz, CDCl3): δ = 192.8, 159.3, 140.3,136.5, 133.2, 132.7, 129.7, 129.1, 128.0, 122.4, 117.4, 117.1, 115.1, 113.0,112.6, 55.2, 54.8. HRMS (ESI): m / z [M + H]+ calcd for: C20H17N2O2S: 349.1011; found: 349.1012. 25. Preparation of compound II-y: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-phenyl-3-(prop-2-yn-1-ylamino)-3-(m-tolyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-y. Yield: 378 mg, 57%. Melting point: 127–129 °C. 1H NMR (400 MHz, CDCl3): d = 7.55–7.50 (m, 2H), 7.31–7.26(m, 1H), 7.15 (t, J = 7.7 Hz, 2H), 7.07–6.98 (m, 3H), 6.97–6.92 (m, 1H), 5.54(d, J = 1.1 Hz, 1H), 5.37 (d, J = 1.2 Hz, 1H), 4.38 (s, 2H), 2.15 (s, 3H). 13 CNMR (101 MHz, CDCl3): d = 193.0, 141.3, 138.3, 136.7, 133.0, 132.5, 131.9,131.6, 131.0, 129.0, 128.5, 127.8, 127.0, 117.1, 112.7, 112.6, 54.9, 21.0.HRMS (ESI): m / z [M + H] + calcd for: C 20 H 17 N2OS: 333.1062; found: 333.1067. 26. Preparation of compound II-z: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(3-fluorophenyl)-1-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-z. Yield: 463 mg, 69%. Melting point: 140–143 °C. 1 H NMR (400 MHz, CDCl3): d = 7.62–7.55 (m, 2H), 7.38–7.32(m, 1H), 7.22 (t, J = 7.8 Hz, 2H), 7.15–7.09 (m, 1H), 7.05–7.02 (m, 1H),6.98–6.93 (m, 1H), 6.91–6.85 (m, 1H), 5.58 (d, J = 1.2 Hz, 1H), 5.41 (d, J =1.2 Hz, 1H), 4.37 (s, 2H). 13 C NMR (101 MHz, CDCl3): d = 192.4, 162.3 (d, J C-F = 247 Hz), 136.3, 134.0, 133.1, 132.3, 130.4 (d, J C-F = 8 Hz), 129.3, 128.2,125.8 (d, J C-F= 3 Hz), 118.7, 117.8 (d, J C-F = 21 Hz), 116.9, 116.7, 113.5,112.4, 54.7. 19 F NMR (376 MHz, CDCl3): d = -111.46 (s, F). HRMS (ESI): m / z [M+ H] + calcd for: C 19 H 14 N2OSF: 337.0811; found: 337.0815. 27. Preparation of compound II-aa: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(3-chlorophenyl)-1-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-aa. Yield: 457 mg, 65%. Melting point: 166–169 °C. 1 H NMR (400 MHz, CDCl3): d= 7.62–7.55 (m, 2H), 7.38–7.32 (m, 1H), 7.22 (t, J = 7.8 Hz, 2H), 7.15–7.09 (m, 1H), 7.05–7.02 (m, 1H),6.98–6.93 (m, 1H), 6.91–6.85 (m, 1H), 5.58 (d, J = 1.2 Hz, 1H), 5.41 (d, J =1.2 Hz, 1H), 4.37 (s, 2H). 13 C NMR (101 MHz, CDCl3): d = 192.4, 162.3 (d, J C-F = 247 Hz), 136.3, 134.0, 133.1, 132.3, 130.4 (d, J C-F = 8 Hz), 129.3, 128.2,125.8 (d, J C-F = 3 Hz), 118.7, 117.8 (d, J C-F = 21 Hz), 116.9, 116.7, 113.5,112.4, 54.7. 19 F NMR (376 MHz, CDCl3): d = -111.46 (s, F). HRMS (ESI): m / z [M+ H] + calcd for: C 19 H 14 N2OSF: 337.0811; found: 337.0815. 28. Preparation of compound II-ab: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-phenyl-3-(prop-2-yn-1-ylamino)-3-(4-propylphenyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-ab. Yield: 396 mg, 55%. Melting point: 122–124 °C. 1 H NMR (400 MHz, CDCl3): d = 7.54–7.47 (m, 2H), 7.25–7.21 (m, 1H), 7.15–7.70 (m, 4H), 6.91 (d, J = 8.1 Hz, 2H), 5.54 (d, J = 1.2Hz, 1H), 5.36 (d, J = 1.2 Hz, 1H), 4.38 (s, 2H), 2.40 (t, J = 7.5 Hz, 2H), 1.44 (q, J = 7.4 Hz, 2H), 0.74 (t, J = 7.3 Hz, 3H). 13 C NMR (101 MHz, CDCl3): d= 193.1, 146.0, 141.7, 136.9, 133.2, 132.3, 130.1, 129.4, 129.2, 128.7,127.8, 116.6, 112.7, 112.6, 55.0, 37.6, 23.9, 13.4. HRMS (ESI): m / z [M + H] + calcd for: C 22 H 21 N2OS: 361.1375; found: 361.1376. 29. Preparation of compound II-ac: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-phenyl-3-(prop-2-yn-1-ylamino)-3-[4-(propyneoxy)phenyl]prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-ac. Yield: 424 mg, 57%. Melting point: 122–125 °C. 1 H NMR (400 MHz, CDCl3): d = 7.58–7.47 (m, 2H),7.32–7.26 (m, 1H), 7.20–7.12 (m, 4H), 6.75–6.65 (m, 2H), 5.53 (d, J = 0.6 Hz,1H), 5.36 (s, 1H), 4.55 (d,J = 2.4 Hz, 2H), 4.37 (s, 2H), 2.48 (s, 1H). 13 CNMR (101 MHz, CDCl3): d = 192.9, 159.4, 141.1, 136.8, 133.2, 132.6, 131.6,129.2, 128.0, 125.3, 116.4, 115.0, 112.7, 112.6, 77.7, 75.9, 55.7, 55.0. HRMS(ESI): m / z [M + H] + calcd for: C 22 H 17 N2O2S: 373.1011; found: 373.1006. 30. Preparation of compound II-ad: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-phenyl-3-(prop-2-yn-1-ylamino)-3-(thiophen-2-yl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-ad. Yield: 317 mg, 49%. Melting point: 158–161 °C. 1 H NMR (400 MHz, CDCl3): d= 7.66–7.60 (m, 2H), 7.40–7.34 (m, 1H), 7.28 (dd, J = 5.1, 1.2 Hz, 1H), 7.25–7.20 (m, 2H), 6.99 (dd, J = 3.7, 1.2 Hz, 1H), 6.73 (dd, J = 5.1, 3.7 Hz, 1H), 5.56 (d, J = 1.1 Hz, 1H), 5.40 (d, J = 0.8 Hz, 1H), 4.36 (s, 2H). 13 C NMR (101 MHz, CDCl3): d = 192.3,136.2, 133.6, 133.3, 132.9, 132.8, 130.9, 129.1, 128.2, 127.6, 118.3, 113.3,112.4, 55.0. HRMS (ESI): m / z [M + H] + calcd for: C 17 H 13 N2OS2: 325.0469; found:325.0470. 31. Preparation of compound II-ae: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(naphthyl-2-yl)-1-phenyl-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-ae. Yield: 368 mg, 50%. Melting point: 164–167 °C. 1 H NMR (400 MHz, CDCl3): d = 7.60 (d, J = 7.3 Hz, 2H),7.50–7.32 (m, 7H), 7.22 (t, J = 8 Hz, 3H), 5.59 (s, 1H), 5.43 (s, 1H), 4.39 (s, 2H). 13 C NMR (101 MHz, CDCl3): d = 192.2, 137.7, 136.2, 135.4, 133.3,132.4, 132.1, 131.9, 130.2, 130.1, 129.4, 128.4, 128.3, 125.7, 125.6, 124.7,121.9, 119.7, 113.8, 112.3, 54.6. HRMS (ESI): m / z [M + H] + calcd for:C 23 H 17 N2OS: 369.1062; found: 369.1058. 32. Preparation of compound II-af: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(4-chlorophenyl)-3-(4-methoxyphenyl)-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-af. Yield: 382 mg, 50%. Melting point: 118–120 °C. 1 H NMR (400 MHz, CDCl3): d = 7.49–7.44 (m, 2H),7.17–7.10 (m, 4H), 6.68–6.64 (m, 2H), 5.53 (s, 1H), 5.36 (s, 1H), 4.37 (s,2H), 3.70 (s, 3H).13C NMR (101 MHz, CDCl3): δ = 191.7, 161.8, 141.9, 138.7,135.2, 133.1, 131.7, 130.5, 128.3, 124.2, 115.5, 114.3, 112.7, 112.6, 55.3,55.1. HRMS (ESI): m / z [M + H]+ calcd for: C20H16N2O2SCl: 383.0621; found:383.0625. 33. Preparation of compound II-ag: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(prop-2-yn-1-ylamino)-1,3-bis(p-tolyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-ag. Yield: 422 mg, 61%. Melting point: 145–146 °C. 1 H NMR (400 MHz, CDCl3): d = 7.52 (d, J = 8.3 Hz, 2H), 7.16–7.11 (m, 2H), 6.98 (dd, J = 14.9, 8.0 Hz, 4H), 5.51 (d, J = 1.1 Hz, 1H), 5.35(d, J = 1.1 Hz, 1H), 4.36 (s, 2H), 2.27 (s, 3H), 2.20 (s, 3H). 13 C NMR (101MHz, CDCl3): d = 192.3, 143.8, 141.1, 139.9, 133.8, 133.1, 129.7, 129.6,129.4, 129.3, 128.8, 116.7, 112.9, 112.5, 54.8, 21.6, 21.3. HRMS (ESI): m / z[M + H] + calcd for: C 21H 19 N2OS: 347.1218; found: 347.1222. 33. Preparation of compound II-ah: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(4-fluorophenyl)-3-(prop-2-yn-1-ylamino)-1-(p-tolyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-ah. Yield: 469 mg, 67%. Melting point: 85–88 °C. 1 H NMR (400 MHz, CDCl3): d = 7.58–7.45 (m, 2H), 7.28–7.21 (m, 2H), 7.01 (d, J = 7.9 Hz, 2H), 6.90–6.80 (m, 2H), 5.53(s, 1H), 5.37(s, 1H), 4.36 (s, 2H), 2.28 (s, 3H). 13 C NMR (101 MHz, CDCl3): d = 192.1, 163.7(d, J C-F = 251 Hz), 144.2, 138.2, 133.6, 132.6, 131.8 (d, J C-F= 9 Hz), 129.5,128.9, 128.3 (d, J C-F = 2 Hz), 117.7, 115.9 (d, J C-F = 22 Hz), 113.0, 112.6,54.7, 21.5. 19 F NMR (376 MHz, CDCl3): d = -108.47 (s, F). HRMS (ESI): m / z [M +H] + calcd for: C 20 H 16 FN2OS: 351.0967; found: 351.0969. 34. Preparation of compound II-ai: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(4-fluorophenyl)-1-(4-methoxyphenyl)-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-ai. Yield: 505 mg, 69%. Melting point: 117–120 °C. 1 H NMR (400 MHz, CDCl3): d= 7.68–7.59 (m, 2H),7.29–7.23 (m, 2H), 6.92–6.84 (m, 2H), 6.74–6.68 (m, 2H), 5.54 (d, J = 1.2 Hz, 1H), 5.38 (d, J = 1.2 Hz, 1H), 4.36 (s, 2H), 3.79 (s, 3H). 13 C NMR (101 MHz, CDCl3): d = 190.8, 163.8 (d, J C-F = 251 Hz), 163.7, 137.1, 132.5, 131.9, 131.7(d, J C-F = 9 Hz), 128.8, 128.3 (d, J C-F = 3 Hz), 117.7, 116.0 (d, J C-F = 22 Hz),113.6, 113.1, 112.7, 55.5, 54.7. 19 F NMR (376 MHz, CDCl3): d = -108.43 (s, F).HRMS (ESI): m / z [M + H] + calcd for: C 20 H 16 N2O2FS: 367.0917; found: 367.0922. 35. Preparation of compound II-aj: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(3-chlorophenyl)-3-(prop-2-yn-1-ylamino)-1-(m-tolyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-aj. Yield: 519 mg, 71%. Melting point: 104–105 °C. 1 H NMR (400 MHz, CDCl3): d = 7.38–7.33 (m, 2H), 7.22(t, J = 1.9 Hz, 1H), 7.17–7.05 (m, 5H), 5.57 (d, J = 1.2 Hz, 1H), 5.40 (d, J = 1.3 Hz, 1H), 4.37 (s, 2H), 2.26 (s, 3H). 13 C NMR (101 MHz, CDCl3): d =192.5, 138.6, 138.0, 136.3, 134.6, 133.8, 132.4, 130.7, 129.9, 129.8, 129.7,128.0, 127.9, 126.5, 119.1, 113.4, 112.4, 54.7, 21.1. HRMS (ESI): m / z [M + H] + calcd for: C 20 H 16N2OSCl: 367.0672; found: 367.0676. 36. Preparation of compound II-ak: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(4-fluorophenyl)-3-(prop-2-yn-1-ylamino)-3-(4-propylphenyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-ak. Yield: 386 mg, 51%. Melting point: 114–116 °C. 1 H NMR (400 MHz, CDCl3): d = 7.58–7.48 (m, 2H),7.12 (d, J = 8.2 Hz, 2H), 6.94 (d, J = 8.1 Hz, 2H), 6.79 (t, J = 8.6 Hz, 2H),5.55 (s, 1H), 5.38 (s, 1H), 4.38 (s, 2H), 2.43 (t, J = 7.4 Hz, 2H), 1.46 (q, J = 7.4 Hz, 2H), 0.76 (t, J = 7.3 Hz, 3H). 13 C NMR (101 MHz, CDCl3): d=191.5, 164.9 (d, J C-F = 253 Hz), 146.4, 141.8, 133.2 (d, J C-F = 3 Hz), 133.0, 131.7 (d, J C-F = 9 Hz), 130.1, 129.3, 128.9, 116.4, 115.0 (d, J C-F = 22 Hz),112.8, 112.6, 55.0, 37.6, 24.0, 13.3. 19 F NMR (376 MHz, CDCl3): d = -105.45(s, F). HRMS (ESI): m / z [M + H] + calcd for: C 22 H 20 FN2OS: 379.1280; found:379.1279. 37. Preparation of compound II-al: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(prop-2-yn-1-ylamino)-1-(thiophen-2-yl)-3-(m-tolyl)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-al. Yield: 452 mg, 67%. Melting point: 143–146 °C. 1 H NMR (400 MHz, CDCl3): d = 7.46 (dd, J = 4.9, 1.2Hz, 1H), 7.36 (dd, J = 3.8, 1.2 Hz, 1H), 7.17–7.04 (m, 4H), 6.82 (dd, J =4.9, 3.8 Hz, 1H), 5.53 (d, J = 1.2 Hz, 1H), 5.37 (q, J = 1.1 Hz, 1H), 4.34(s, 2H), 2.22 (s, 3H). 13 C NMR (101 MHz, CDCl3): d = 184.4, 142.4, 139.3,138.6, 134.7, 134.3, 132.7, 132.0, 131.6, 130.4, 128.7, 127.6, 126.7, 117.3,112.8, 112.7, 54.8, 21.1. HRMS (ESI): m / z [M + H]+ calcd for: C 18 H 15 N2OS2:339.0626; found: 339.0631. 38. Preparation of compound II-am: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-1-(furan-2-yl)-3-(3-methoxyphenyl)-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-am. Yield: 459 mg, 68%. Melting point: 155–157 °C. 1 H NMR (400 MHz, CDCl3): d = 7.28–7.26 (m, 1H),7.16 (t, J = 7.9 Hz, 1H), 6.96–6.89 (m, 2H), 6.85–6.79 (m, 2H), 6.26 (dd, J =3.6, 1.7 Hz, 1H), 5.54 (d, J = 1.2 Hz, 1H), 5.37 (d, J = 1.1 Hz, 1H), 4.33(s, 2H), 3.72 (s, 3H). 13 C NMR (101 MHz, CDCl3): d= 179.4, 159.5, 151.1,146.8, 140.5, 133.4, 132.8, 129.8, 122.1, 119.6, 117.1, 116.7, 114.5, 112.9,112.6, 112.3, 55.4, 54.8. HRMS (ESI): m / z [M + H] + calcd for: C 18 H 15 N2O3S:339.0803; found: 339.0808. 39. Preparation of compound II-an: A solution of 1,3-dibromo-5,5-dimethylimidazolium-2,4-dione (1 mmol) dissolved in N,N-dimethylformamide (1 mL) was added dropwise to a solution of (Z)-3-(3-methoxyphenyl)-1-(naphth-2-yl)-3-(prop-2-yn-1-ylamino)prop-2-en-1-one (2 mmol) dissolved in N,N-dimethylformamide (1 mL). The reaction mixture was stirred at room temperature for 30 minutes, then heated at 60 °C for 2 hours. Subsequently, a solution of potassium thiocyanate (2 mmol) dissolved in N,N-dimethylformamide (4 mL) was added dropwise, and the reaction mixture was stirred at 60 °C for another 2 hours. After the reaction was complete, the mixture was cooled to room temperature, and ethyl acetate (30 mL) was added. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in N,N-dimethylformamide (4 mL), followed by the addition of sodium hydroxide (2 mmol) and 15-crown ether-5 (2 mmol). The reaction mixture was stirred at room temperature for 2 hours. After the reaction was complete, ethyl acetate (20 mL) was added, and the mixture was washed three times with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The crude product was further purified by rapid column chromatography to give compound II-an. Yield: 493 mg, 62%. Melting point: 128–131°C. 1 H NMR (400 MHz, CDCl3): d = 8.10 (d, J = 1.6 Hz,1H), 7.82–7.73 (m, 2H), 7.69–7.63 (m, 2H), 7.55–7.46 (m, 2H), 6.98–6.85 (m,2H), 6.75 (dd, J= 2.5, 1.7 Hz, 1H), 6.56–6.52 (m, 1H), 5.58 (d, J = 1.2 Hz, 1H), 5.41 (d, J = 1.2 Hz, 1H), 4.44 (s, 2H), 3.56 (s, 3H). 13 C NMR (101 MHz, CDCl3): d = 192.5, 159.3, 140.2, 135.2, 133.8, 133.4, 132.7, 131.8, 131.3,129.7, 129.2, 128.5, 128.1, 127.7, 126.7, 124.5, 122.2, 117.5, 116.9, 115.0,113.1, 112.7, 55.2, 54.9. HRMS (ESI): m / z [M + H] + calcd for: C 24 H 19 N2O2S:399.1167; found: 399.1169. Example 2: Pharmacological effects of cyanamide-based 3,4-dihydro-2H-1,4-thiazide compounds: 1. Cell culture: Human lung adenocarcinoma cells NCI-H820 were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS); 3T3 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum. All cells were cultured in a cell incubator at 37°C with 5% carbon dioxide.

[0035] 2. MTT assay: Human lung adenocarcinoma cells NCI-H820 were collected, counted, and seeded in 96-well plates at a density of 2000 cells / 200 µL / well. After cell attachment, different concentrations of the compound were added and incubated for 72 hours. Subsequently, 20 µL of MTT solution (5 mg / mL) was added to each well, and incubation continued for approximately 4 hours. After discarding the supernatant, the precipitate was dissolved in DMSO, and the absorbance at 570 nm was measured.

[0036] These compounds all exhibited moderate to potent antiproliferative activity. Compared to R... 2 Substitutionalized analogues (II-s-II-ae), R 1 Substituents on the aromatic ring (II-b-II-r) generally enhance antiproliferative efficacy, with para-substituted derivatives showing higher activity than meta-substituted derivatives. Compounds II-b and II-c exhibit the strongest activity: II-b (para-methoxy) has an IC50 of [missing value].50 It is 6.8 nM, compared to Ⅱ-a (IC). 50 = 0.13 µM) increased by 19 times. Halogen substitution (II-d-II-g) generally enhances efficacy (IC50). 50 = 0.016-0.31 µM), while the larger tert-butyl group (II-h) significantly reduces activity. Meta-substituted analogs (II-j, II-k, II-m) show reduced efficacy (IC50). 50 = 0.32-0.47 µM), consistent with steric hindrance. Analogs containing naphthyl, furanyl, or thiophene groups (II-n-II-q) retain strong activity, while ester compounds II-r show lower cytotoxicity (IC50). 50 =1.90 µM). In R 2 In substituted compounds, representative examples (such as II-u, II-x, II-z, II-aa, and II-ad) maintain submicromolar activity. Most disubstituted aryl analogs (II-af-II-an) still exhibit potent activity (IC50). 50 = 0.013-1.13 µM), except for II-ak (IC). 50 = 12.06 µM), further illustrating that excessive steric hindrance can have an adverse effect on drug efficacy.

[0037] Table 1. Activity of derivatives II-a to II-an as evaluated by MTT assay In vivo pharmacodynamic evaluation: Experimental animals were housed in a specific pathogen-free (SPF) environment. The patient-derived xenograft (PDX) model was provided by Beijing IDMO Co., Ltd., and was established based on human lung cancer tissue. Human lung cancer tumor tissue excised from PDX model mice was cut into 5-8 mm pieces. 3 Small pieces were subcutaneously inoculated into the ventral side of BAL B / c nude mice. When the average transplanted tumor volume reached approximately 25 mm... 3 Approximately 7 days after inoculation, tumor-bearing mice were randomly divided into a solvent control group, a II-b treatment group (5 mg / kg), and a II-c treatment group (10 mg / kg), with 5 mice in each group. Compounds II-b and II-c were dissolved in corn oil containing 5% DMSO and administered intraperitoneally every three days for a total of six doses; the control group received only an equal volume of solvent. Tumor growth rate was monitored every two days by measuring the long and short diameters using electronic calipers, and the growth was calculated using the formula: Volume = 1 / 2 × (long diameter) × (short diameter). 2 Tumor volume was calculated; body weight was also recorded to assess drug tolerance. To evaluate in vivo efficacy, a PDX mouse model of lung cancer was established, and mice were injected intraperitoneally with either II-b or II-c every three days.

[0038] The results are as follows Figure 1 As shown, treatment with either II-b (5 mg / kg) or II-c (10 mg / kg) significantly reduced tumor volume and weight, inhibiting tumor growth. Notably, II-b exhibited superior tumor-suppressive effects compared to II-c, making it a highly promising lead compound for future development.

[0039] The above description is merely an embodiment of the present invention and is not intended to limit the present invention in any way. The present invention may also have other embodiments based on the above description, which will not be listed hereafter. Therefore, any simple modifications, equivalent changes, and alterations made by those skilled in the art to the above embodiments based on the technical essence of the present invention without departing from the scope of the present invention shall still fall within the scope of the present invention.

Claims

1. A cyanamide-type 3,4-dihydro-2H-1,4-thiazine compound of formula (II), ; wherein R 1 and R 2 is aryl or heterocyclyl, aryl is phenyl, substituted phenyl, heteroaryl is furanyl, thienyl, substituted furanyl, substituted thienyl.

2. The compound according to claim 1 is, preferably, compound II-a to II-an. 。 3. A method for preparing compound (II), the method comprising the following steps: (1) using N-propargyl enamine ketone (I) as raw material, 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (DBDMH) as bromination promoter, inorganic thiocyanate as cyanide source, a certain reaction solvent, mixed in a certain proportion, and at a certain temperature, N-propargyl enamine ketone first undergoes selective thiocyanation reaction to generate thiocyanate intermediate; (2) without separation, sodium hydroxide and crown ether are directly added to the intermediate, and at a certain temperature, the reaction yields 3,4-dihydro-2H-1,4-thiazine compound (II).

4. The production method according to claim 3, characterized by, The N-propargyl β-enamine ketone has the structure shown in formula (I). 。 5. The method of claim 3, wherein The molar ratio of N-propargylenamine ketone (I), 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione, potassium thiocyanate, sodium hydroxide and 15-ether-5 is 1.0:0.5:1.0:1.0:1.

0.

6. The method of claim 3, wherein, The inorganic thiocyanate mentioned in step (1) is selected from one or more of potassium thiocyanate, sodium thiocyanate, or ammonium thiocyanate.

7. The method of claim 3, wherein, The organic solvent mentioned in step (1) is N,N-dimethylformamide.

8. The method of claim 3, wherein, The reaction temperature in step (1) is 40–80°C, preferably 60°C.

9. The method of claim 3, wherein, The crown ether mentioned in step (2) is 15-crown ether-5.

10. The method of claim 3, wherein, The reaction temperature in step (2) is 0 to 80°C, preferably 25°C.

11. Use of the compound of any one of claims 1 and 2 in the preparation of a medicament for treating cancer or an adjuvant medicament for treating cancer, wherein the cancer is leukemia, breast cancer, prostate cancer, nasopharyngeal carcinoma, colorectal cancer, lung cancer, liver cancer, esophageal cancer, gastric cancer, intestinal cancer, kidney cancer, oral cancer, Hodgkin's lymphoma, pancreatic cancer, rectal cancer, cervical cancer, non-Hodgkin's lymphoma, glioma, melanoma, bladder cancer, ovarian cancer, thyroid cancer, or Kaposi's sarcoma.

12. A pharmaceutical composition for treating cancer, said pharmaceutical composition comprising an effective amount of the compound of any one of claims 1 and 2 and a pharmaceutically acceptable carrier or other anticancer agent.